Business NewsPR NewsWire • Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China

Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China

Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China

DARMSTADT, Germany, July 28, 2016 /PRNewswire/ -- Not intended for UK- or US-based media Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017  Merck is the first pharmaceutical company to...

View More : http://www.prnewswire.com/news-releases/merck-and-amoydx-collaborate-to-bring-liquid-biopsy-ras-biomarker-testing-to-chi...
Releted News by prnewswire
Euronav NV - Preliminary Second Quarter & Half Year Results 2016
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
Global Gaming Reenergized: Augmented Reality, Location Based Gaming and Connected Toys Fuel Mobile Gaming, finds Frost & Sullivan
Dodge Expands Its Partnership With Fathead and Takes Building the Ultimate Dodge Customized Space to a New Level
Rokkan's West Coast Operation Flourishes Under New Leadership